EC grants orphan drug designation to aTyr Pharma's Resolaris for treatment of FSHD

aTyr Pharma, Inc. ("aTyr"), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address rare diseases, announced today the European Commission (EC) has granted orphan drug designation to Resolaris™ for the treatment of facioscapulohumeral muscular dystrophy (FSHD). Resolaris™, an investigational new drug representing aTyr's first Physiocrine-based product candidate in the clinic, is being developed as a first-in-class intravenous protein therapeutic for the treatment of rare myopathies with an immune component.

"Our mission is to develop medicines that will make a meaningful difference to patients impacted by debilitating rare diseases. We are very pleased that the EMA has recognized the potential of Resolaris™ for patients suffering from FSHD," said John Mendlein, Ph.D., CEO and executive chairman of aTyr Pharma. "The Agency's decision is an important advancement for our promising Physiocrine-based medicines, and marks a key milestone in our strategy to deliver Resolaris™ to address the unmet needs of patients with this rare disease."

aTyr previously announced the first patient study of Resolaris™ in adults with FSHD, a rare and severe genetic myopathy for which there are currently no approved treatments. The Phase 1b/2 study is a double-blind, placebo-controlled, multiple ascending dose trial in up to 44 FSHD patients currently enrolling at multiple sites in the European Union (EU).


aTyr Pharma


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
New peptide derivatives that target the SARS-CoV-2 spike protein